Medical Information Only: This medication is not sold on this site. The information provided is for reference purposes only. Please consult your local physician or pharmacist for treatment.

Toremifenum [Latin]: Full Drug Profile

Medically reviewed by Min Clinic Staff | Updated: January 2026

Toremifenum [Latin] - General Information

A first generation selective estrogen receptor modulator (SERM). Like tamoxifen, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. [PubChem]

 

Pharmacology of Toremifenum [Latin]

Toremifenum [Latin] is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer. Toremifenum [Latin] is a nonsteroidal agent that has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Toremifenum [Latin] inhibits the induction of rat mammary carcinoma induced by dimethylbenzanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, Toremifenum [Latin] appears to exert its antitumor effects by binding the estrogen receptors. In cytosols derived from human breast adenocarcinomas, Toremifenum [Latin] competes with estradiol for estrogen receptor protein.

 

Toremifenum [Latin] for patients

Patient Information:

Vaginal bleeding has been reported in patients using Toremifene. Patients should be informed about
this and instructed to contact their physician if such bleeding occurs.

Patients with bone metastases should be informed about the typical signs and symptoms of hypercalcemia
and instructed to contact their physician for further assessment if such signs or symptoms occur.

 

Toremifenum [Latin] Interactions

Drugs that decrease renal calcium excretion, eg, thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. There is a known interaction between antiestrogenic compounds of the triphenylethylene derivative class and coumarin-type anticoagulants (eg, warfarin), leading to an increased prothrombin time. When concomitant use of anticoagulants with FARESTON is necessary, careful monitoring of the prothrombin time is recommended.

Cytochrome P450 3A4 enzyme inducers, such as phenobarbital, phenytoin, and carbamazepine increase the rate of toremifene metabolism, lowering the steady-state concentration in serum. Metabolism of toremifene may be inhibited by drugs known to inhibit the CYP3A4-6 enzymes. Examples of such drugs are ketoconazole and similar antimycotics as well as erythromycin and similar macrolides. This interaction has not been studied and its clinical relevance is uncertain.

 

Toremifenum [Latin] Contraindications

FARESTON is contraindicated in patients with known hypersensitivity to the drug.

 

Additional information about Toremifenum [Latin]

Toremifenum [Latin] Indication

For the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or receptor-unknown tumors

Mechanism Of Action
Toremifenum [Latin] is a nonsteroidal triphenylethylene derivative. Toremifenum [Latin] binds to estrogen receptors and may exert estrogenic, antiestrogenic, or both activities, depending upon the duration of treatment, animal species, gender, target organ, or endpoint selected. The antitumor effect of toremifene in breast cancer is believed to be mainly due to its antiestrogenic effects, ie, its ability to compete with estrogen for binding sites in the cancer, blocking the growth-stimulating effects of estrogen in the tumor.
Generic Name
Toremifene
Drug Category
Antineoplastic Agents; Selective Estrogen Receptor Modulators
Drug Type
Small Molecule; Approved; Investigational
Other Brand Names containing Toremifene
Acapodene; Fareston; Farestone; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; Z-Toremifene;
Absorption
Well absorbed
Protein Binding
Greater than 99.5%
Biotransformation
Hepatic. Mainly by CYP3A4.
Half Life
5 days
Dosage Forms of Toremifenum [Latin]
Tablet Oral
Chemical IUPAC Name
2-[4-[(Z)-4-chloro-1,2-di(phenyl)but-1-enyl]phenoxy]-N,N-dimethylethanamine
Chemical Formula
C26H28ClNO
Organisms Affected
Humans and other mammals